Efficacy and Safety of Induction Chemotherapy and/or External Beam Radiotherapy Followed by Brachytherapy in Patients With Tongue Cancer.

Autor:	Yoshimura RI; Department of Radiation Therapeutics and Oncology, Tokyo Medical and Dental University, Tokyo, Japan; ysmrmrad@tmd.ac.jp., Toda K; Department of Radiation Therapeutics and Oncology, Tokyo Medical and Dental University, Tokyo, Japan., Watanabe H; Department of Oral Radiology, Tokyo Medical and Dental University, Tokyo, Japan., Kaida A; Department of Oral Radiation Oncology, Tokyo Medical and Dental University, Tokyo, Japan., Harada H; Department of Oral and Maxillofacial Surgery, Tokyo Medical and Dental University, Tokyo, Japan., Asakage T; Department of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, Japan., Miura M; Department of Oral Radiation Oncology, Tokyo Medical and Dental University, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2021 Dec; Vol. 41 (12), pp. 6259-6266.
DOI:	10.21873/anticanres.15446
Abstrakt:	Background/aim: To evaluate the outcomes of induction chemotherapy and/or external beam radiotherapy (EBRT) followed by brachytherapy (BT) in patients with tongue cancer who had a waiting period for BT or a large tumor that was not suitable for BT. Patients and Methods: As an induction therapy, chemotherapy with tegafur/gimeracil/oteracil (S-1), EBRT or both S-1 chemotherapy and EBRT was prescribed. BT was performed using Au-198 grains or Ir-192 pins. Local control (LC), lymph node metastasis-free survival (LNMFS), overall survival (OS), and complication rates were calculated. Results: Forty-nine patients were enrolled in this study. The 3-year LC, LNMFS, and OS rates for cT1-2 patients were 84%, 45%, and 69%, respectively. The 3-year LC, LNMFS, and OS rates for cT3 patients were 77%, 58%, and 79%, respectively. The incidence of Grade 3 or 4 complications was 6%. Conclusion: Induction therapy contributed to the efficacy of the subsequent BT in LC rate. (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu